Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer
Frontiers in Oncology · 28.05.2026 · 16
DOI: 10.3389/fonc.2026.1837880 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 28.05.2026. Verfasst von Zhoujunyi Tian und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Neoadjuvant chemoimmunotherapy and adjuvant immunotherapy is a standard of care for resectable non-small cell lung cancer. However, high non-adherence rates challenge its implementation and benefits. We assessed the risks and long-term outcomes of completing this full regimen versus non-completion in a real-world setting.
Methods
Patients with resectable non-small cell lung cancer at clinical stage IB-IIIB who received neoadjuvant chemoimmunotherapy followed by surgery were included. Patients were divided into a completed group (n=37), who received four cycles of perioperative chemoimmunotherapy and one year of adjuvant immunotherapy, and a non-completed group (n=127). Inverse Probability of Treatment Weighting was used to adjust baseline characteristics. Kaplan-Meier curves compared recurrence-free survival, overall survival, and cumulative hazard of adverse events. Cox regression models assessed predictors for recurrence and subgroup analyses were performed.
Results
No significant differences were in recurrence-free survival (P = 0.85) or overall survival (P = 0.34) between the two groups. Positive pathological nodal status was an independent predictor of recurrence, while completion status was not (adjusted hazard ratio 1.14, 95% CI 0.24-5.50, P = 0.87). The completed group experienced a higher incidence of any-grade adverse events (AEs), but no significant increase in Grade 3/4 AEs. Subgroup analysis revealed a notable recurrence benefit from completion in patients who were aged <65 years and ECOG score 0.
Conclusion
Completing perioperative chemoimmunotherapy protocol did not significantly increase the risk of severe AEs, but also failed to demonstrate a survival benefit. Prospective studies and extended follow-up duration were needed to verify the conclusions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, China-Japan Friendship Hospital, Beijing, China.
- Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China.
Zitieren
APA
Tian, Z., Yang, H., Zhang, J., Yu, Q., Liu, D., Yang, M., Zhang, Z., & Liang, C. (2026). Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1837880
Vancouver
Tian Z, Yang H, Zhang J, Yu Q, Liu D, Yang M, et al. Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1837880
BibTeX
@article{Tian2026,
author = {Tian, Zhoujunyi and Yang, Haoshuai and Zhang, Jin and Yu, Qiduo and Liu, Deruo and Yang, Meng and Zhang, Zhenrong and Liang, Chaoyang},
title = {Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer},
journal = {Frontiers in Oncology},
year = {2026},
volume = {16},
doi = {10.3389/fonc.2026.1837880}
}
EUVIMED